Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
XBIT

XBIT - XBiotech Inc Stock Price, Fair Value and News

$2.62-0.09 (-3.32%)
Market Closed

53/100

XBIT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

53/100

XBIT

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$2.97

Target 3M

$2.75

Target 6M

$2.82

XBIT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XBIT Price Action

Last 7 days

2.8%

Last 30 days

8.7%

Last 90 days

9.2%

Trailing 12 Months

-24.7%

XBIT RSI Chart

XBIT Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

XBIT Valuation

Market Cap

79.9M

Price/Earnings (Trailing)

-2.74

Price/Sales (Trailing)

12.18

EV/EBITDA

2.52

Price/Free Cashflow

-3.35

XBIT Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$2.97

Target 3M

$2.75

Target 6M

$2.82

XBIT Fundamentals

XBIT Revenue

Revenue (TTM)

6.6M

Rev. Growth (Yr)

-39.76%

Rev. Growth (Qtr)

-6.73%

XBIT Earnings

Earnings (TTM)

-29.2M

Earnings Growth (Yr)

-19.8%

Earnings Growth (Qtr)

-242.14%

XBIT Profitability

EBT Margin

-442.85%

Return on Equity

-17.45%

Return on Assets

-16.91%

Free Cashflow Yield

-29.85%

XBIT Investor Care

Shares Dilution (1Y)

0.01%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20258.7M7.5M6.6M0
202410.3M10.5M10.3M9.8M
20238.0M9.0M10.5M10.4M
202214.8M11.2M7.6M4.0M
202136.2M25.2M19.2M18.4M
202017.9M26.6M35.3M44.0M
2019414.5K358.5K508.5K9.2M
2018368.5K361.5K338.5K400.5K
2017125.1K201.3K277.4K353.5K
201600049.0K
20150000
20140000
20130000
Get all data in R, Python etc through our Historical Stock Data APIs

About XBiotech Inc

XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
 CEO
 WEBSITExbiotech.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES84

XBiotech Inc Frequently Asked Questions

XBIT is the stock ticker symbol of XBiotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of XBiotech Inc is 79.88 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check XBIT's fair value in chart for subscribers.

The fair value guage provides a quick view whether XBIT is over valued or under valued. Whether XBiotech Inc is cheap or expensive depends on the assumptions which impact XBiotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XBIT.

As of Wed Jan 28 2026, XBIT's PE ratio (Price to Earnings) is -2.74 and Price to Sales (PS) ratio is 12.18. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XBIT PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, XBiotech Inc has provided -0.108 (multiply by 100 for percentage) rate of return.